Placebo
DrugOral prophylaxis followed by placement of placebo gel
Other names: inactive drug
NCT Number: NCT03204097
Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects
Looking for future studies?
Notify Me25 year–50 year
All sexes
Interventional
Phase 2 / Phase 3
Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects.
Methods: Ninety patients with mandibular buccal class II furcation defects were randomly allocated into three treatment groups: SRP plus placebo gel (group 1), SRP plus 1% ALN gel (group 2) and SRP plus AV gel (group3). Clinical and radiographic parameters were recorded at baseline and gel were delivered at respective site. Then again all clinical and radiographic parameters were recorded after 6 and 12 months from baseline.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Systemically healthy patients with mandibular class II furcation defects and asymptomatic endodontically vital mandibular molars with radiolucency in furcation area with PD ≥ 5mm and horizontal PD ≥ 3mm and with no history of antibiotic or any periodontal therapy in past 6 months were included in the study -
Exclusion criteria
Subjects with any known systemic disease, allergic to alendronate or aloe vera, on systemic alendronate therapy, alcoholics, tobacco users, pregnant or lactating women
-
Oral prophylaxis followed by placement of placebo gel
Other names: inactive drug
Oral prophylaxis followed by placement of Alendronate gel
Other names: ALN
Oral prophylaxis followed by placement of Aloe Vera gel
Other names: AV
Time frame: baseline, 6 & 12 months
Assessed in percentage
Time frame: baseline, 6 & 12 months
scale 0-3
Time frame: baseline, 6 & 12 months
scale 0-3
Time frame: baseline, 6 & 12 months
measured in mm
Time frame: baseline, 6 & 12 months
measured in mm
Time frame: baseline, 6 & 12 months
measured in mm
Government Dental College and Research Institute, Bangalore
Other
1% Alendronate and Aloevera Gel Local Host Modulating Agents in Chronic Periodontitis Subjects With Class II Furcation Defects: A Randomized Controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06893107
Chronic Disease, Chronic Periodontitis
Fujairah, Emirate of Fujairah, United Arab Emirates
View Trial DetailsNCT04274244
Alveolar Bone Loss, Bone Diseases
Valencia, Spain
View Trial DetailsNCT07671456
Aggressive Periodontitis, Chronic Disease
View Trial DetailsNCT03863249
Alveolar Bone Loss, Bone Diseases
Valencia, Spain
View Trial Details